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Abstract The aim of the present study was to evaluate a
new improved multiplex polymerase chain reaction (PCR)
hybridisation assay to detect multidrug-resistant tuberculo-
sis. The assay, developed to detect rifampin (rpoB) and
isoniazid (katG) gene mutations causing Mycobacterium
tuberculosis resistance, was recently extended to include
inhA gene mutations that code for low-level isoniazid
resistance. Interpretable results were obtained in 115
isolates and in all smear-positive clinical specimens.
Rifampin resistance was correctly identified in all speci-
mens and in 20 of 21 (95%) multidrug-resistant isolates
compared to BACTEC 460TB. Isoniazid resistance corre-
lated in 18 of 22 (82%) specimens, in 31 of 31 (100%)
high-level and 24 of 28 (86%) low-level isoniazid-resistant
isolates. The assay was rapid, easy to perform and directly
applicable in smear-positive specimens. We predict that the
assay may be a useful tool to combat and prevent new cases
of multi- and extensively drug-resistant tuberculosis.
Introduction
Multidrug-resistant tuberculosis (MDR-TB) is defined as
disease caused by Mycobacterium tuberculosis resistant to
at least rifampin (RIF) and isoniazid (INH), the two most
important first-line anti-TB drugs. MDR-TB represents a
serious problem for clinical management, and has become an
important public health issue. The rapid detection of drug
resistance permits the establishment of an effective treatment
regimen, minimises the risk of further resistance develop-
ment and limits the spread of drug-resistant M. tuberculosis.
Over 400,000 MDR-TB cases emerge every year, 50%
amongst new TB cases and 50% in previously treated TB
patients [1]. Approximately 5–7% of these cases are
expected to have extensively drug-resistant TB (XDR-TB)
[2]. MDR-TB and XDR-TB are associated with an extremely
high mortality, especially in the human immunodeficiency
virus (HIV) coinfected [3, 4]. Therefore, rapid methods to
determine drug resistance are urgently in demand.
Resistance to INH is conferred by mutations within the
catalase-peroxidase enzyme gene (katG in 50–95% of
resistant strains), the enoyl-acyl carrier protein reductase
gene (inhA in 15–35% of resistant strains) and in the ahpC–
oxyR intergenic region (10–15% of resistant strains) [5–9].
Resistance to RIF is predominantly linked to mutations
within the RNA polymerase, B-subunit gene (rpoB in
approximately 96% of all RIF-resistant stains tested) [10].
Recently, a combined multiplex polymerase chain reaction
(PCR) and DNA strip hybridisation assay, the GenoType
MTBDRplus (GTplus), was further developed from the
original GenoType MTBDR (GT) version (Hain Lifescience,
Nehren, Germany). The technique combines a multiplex PCR
followed by the hybridisation to specific membrane-bound
probes for the identification of either wild-type (WT) or
specific mutations. In addition to the detection of mutations in
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the genes conferring resistance to RIF (rpoB) and high-level
INH (katG), as applied in the original version, probes to detect
mutations within the inhA gene causing low-level INH
resistance have been included. In the new version of the
DNA strip, the inhA gene is covered by two inhA WT (−15,
−16 and −8 nucleic acid positions) and four inhA mutation
probes (C15T, A16G, T8C and T8A). In addition, three more
rpoB WT probes targeting codons 505–533 were included.
The aim of the present study was to evaluate the
performance of the new GTplus assay for the rapid
detection of mutations causing RIF and high- or low-level
INH resistance in M. tuberculosis isolates and directly in
clinical specimens. The GTplus assay results were com-
pared to drug susceptibility testing (DST) performed by the
proportion method BACTEC 460TB (Becton Dickinson
Diagnostic Instruments Systems, Sparks, MD).
Materials and methods
The study was carried out at the International Reference
Laboratory of Mycobacteriology, Copenhagen, Statens
Serum Institute (SSI), Denmark.
Isolates and clinical specimens
A total of 115 M. tuberculosis isolates, 53 from SSI,
Denmark, and 62 from the National TB Reference
Laboratory in Lithuania, were included. In order to test
the performance of the additional inhA gene mutation, the
Danish isolates consisted of 28 low-level (0.1 μg/ml) INH-
resistant isolates, five high-level (0.4 μg/ml) INH-resistant
and 20 susceptible strains. The Lithuanian isolates included
a mixture of multidrug-resistant and susceptible strains
representing 20% of the MDR-TB isolates and 10% of the
non-MDR-TB isolates from Lithuania in 2006.
Eighty-one pretreated clinical specimens that consisted
of 61 respiratory specimens (sputum, tracheal secretion,
bronchioalveolar lavage) and 20 non-respiratory specimens
(12 gastric lavage, six lymph node and two tissue biopsies)
were included. Specimens were selected based on smear
grade, nucleic acid amplification, culture and DST results
and were processed by conventional procedures as de-
scribed elsewhere [11]. Smears were stained with auramine-
rhodamine and examined by fluorescent microscopy [12].
Nucleic amplification was performed by strand displace-
ment amplification as previously described [13].
The Lithuanian isolates were sent for reference purposes
to SSI and were, therefore, of no consequence to the
patients from which they had been obtained. None of the
Danish patients had prohibited the use of their tissue
specimens for research (the Registry of Human Tissue
Utilization, National Board of Health, Denmark).
Drug susceptibility testing
DST for RIF, INH, ethambutol and pyrazinamide was
performed in Denmark by using the BACTEC 460TB
system, according to the manufacturer’s instructions [14].
BACTEC 460TB was used as the gold standard and the
critical concentrations were 2.0 μg/ml for RIF and 0.1 μg/ml
for INH. In addition, INH was tested at 0.4 μg/ml, and
2.0 μg/ml in the BACTEC 460TB system. High-level INH
resistance was defined as INH resistance at a concentration
≥0.4 μg/ml according to the Clinical and Laboratory Stand-
ards Institute (CLSI, formerly the National Committee for
Clinical Laboratory Standards [NCCLS]) [15]. The critical
concentrations used were 2.5 μg/ml for ethambutol and
100 μg/ml for pyrazinamide. When drug resistance was
observed for RIF and/or INH, additional DSTwas performed
at concentrations of 1.0 μg/ml for amikacin and 2.0 μg/ml
for ofloxacin.
GenoType MTBDRplus assay
The new DNA strip includes the following probes:
conjugate control (CC), amplification control (AC), M.
tuberculosis complex control (TUB), specific gene locus
controls (rpoB, katG, inhA), WT sequences (rpoB WT1–8,
katG WT, inhAWT1–2), the four most frequent rpoB gene
mutations (D516V, H526Y, H526D, S531L), the two
mutations at codon 315 in the katG gene (S315T1,
S315T2) and the four mutations in the inhA promoter
region (C15T, A16G, T8C, T8A).
Aliquots of 1,000 μl of M. tuberculosis isolate in Dubos
medium (SSI, Copenhagen, Denmark) or a volume of
frozen surplus material (−20°C) of 500 μl NaOH-N-acetyl-
L-cysteine-pretreated clinical specimen were centrifuged at
10,000×g for 15 min. The pellet was resuspended in 100 μl
of distilled water, vortexed, heat inactivated for 20 min at
100°C, lysed by ultrasonification for 15 min at 60°C and
centrifuged at 13,000×g for 5 min.
For amplification, a mixture consisting of 35 μl primer
nucleotide mix, 5 μl of 10× PCR buffer with 20 mM MgCl2
(isolates) or 5 μl of 10× PCR buffer without MgCl2
(clinical specimens), 1 μl of 25 mM MgCl2 (isolates) or
3 μl of 25 mM MgCl2 (clinical specimens), 2 U of FastStart
Taq DNA polymerase (Roche Applied Science, Mannheim,
Germany) and 5 μl supernatant in a final volume of 50 μl
was prepared.
Amplification was performed in a thermocycler (Perkin
Elmer 9600 thermal cycler; Perkin Elmer Corporation,
Norwalk, CT) using the following amplification profile:
initial denaturation of 5 min at 95°C, followed by 10 cycles
of 30 s at 95°C and 2 min at 58°C, and 20 cycles (isolates)
or 30 cycles (clinical specimens) of 25 s at 95°C, 40 s at
53°C and 40 s at 70°C and a final extension step of 8 min at
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70°C. Amplification was visualised by agarose electropho-
resis: amplification control (63 bp), M. tuberculosis
complex control (115 bp), rpoB (166 bp), katG (120 bp)
and inhA (110 bp). Hybridisation was performed using a
pre-programmed Auto-LiPA system (InnoGenetics, Zwij-
naarde, Belgium) and the GTplus DNA strips were
interpreted according to the manufacturer’s instructions, as
shown in Fig. 1.
Sequencing
The DNA sequence analysis of rpoB, katG, inhA and oxyR–
ahpC was performed for samples having discrepant results
between DST and the assay. For the one isolate which had a
discrepant result by genotype that was susceptible to RIF,
the rpoB gene was subjected to sequencing by a previously
described method [16]. Sequencing of the four discrepant
isolates and the four isolates obtained from the four
discrepant clinical samples was performed in the following
regions: katG (codons 315 and 463), fabG1–inhA and the
oxyR–ahpC intergenic region using primers previously
described [17–19]. The PCR conditions used for the katG
codon 315, the fabG–inhA and the oxyR–ahpC intergenic
region were as follows: primers katg1F and katg4F (katG),
519 and 520 (fabG1–inhA) and tomap1 and tomap2 (oxyR–
ahpC) using AmpliTaq Gold (Applied Biosystems, Foster
City, CA) and 1.5 mM MgCl2 (2.5 mM for oxyR–ahpC),
with 30 cycles of 1 min at 95°C, 40 s at 62°C and 1 min at
72°C. PCR conditions for the katG codon 463 analysis
were as follows: primers 542 and 543 were used with the
GC-RICH PCR system (Roche Applied Science, Man-
nheim, Germany) using 0.3-mM GC-RICH resolution and
40 cycles of 1 min at 95°C, 30 s at 50°C and 90 s at 72°C.
The products were sequenced using the BigDye Terminator




Among the 62 Lithuanian isolates analysed by genotype, 21
were resistant to RIF and INH (MDR-TB), five were high-
level INH mono-resistant and 36 were susceptible. Only
one of the 21 (5%) MDR isolates also had XDR M.
tuberculosis. The 53 Danish isolates included 28 low-level
INH mono-resistant isolates, five high-level INH mono-
resistant and 20 susceptible strains. DST performed on the
61 culture-positive clinical specimens identified one isolate
which was MDR M. tuberculosis and 21 were monodrug-
resistant to INH, of which, seven were low-level INH-
resistant and 39 were found to be fully susceptible.
GTplus performance in isolates
Sufficient amplification and interpretable genotype results
was obtained in all isolates. The genotype results were
concordant with BACTEC results in 61 of 62 (98%)
Lithuanian isolates and in 49 of 53 (93%) Danish isolates.
Fig. 1 Representative DNA strip patterns obtained with the Geno-
Type MTBDRplus (GTplus) assay. The positions of the oligonucle-
otide probes are given on the left. The target genes and specific probe
lines are shown from the top to bottom as follows: conjugate control;
amplification control (23S rRNA); Mycobacterium tuberculosis
complex-specific control (23S rRNA); locus control of rpoB ampli-
fication; eight rpoB wild-type (WT) probes; four rpoB mutant probes
with mutations in codons 516, 526 or 531; locus control of katG
amplification; one katG codon 315 WT probe; two katG probes with
mutations in codon 315; locus control of inhA amplification; two inhA
WT probes; and four mutation probes in the inhA promoter region
(−15C/T, −16A/G, −8T/C and −8T/A). Samples with different strip
susceptibility patterns are shown on the right. Lane 1, drug-susceptible
(rpoB, katG, inhA WT); lane 2, rifampin (RIF)-susceptible, low-level
isoniazid (INH)-resistant (rpoB, katG WT, inhA C15T mutation); lane
3, multidrug-resistant tuberculosis (MDR-TB) (rpoB S531L, katG
S315T1, inhA C15T mutation); lane 4, MDR-TB (rpoB H526D, katG
S315T1, inhA C15T mutation); lane 5, RIF susceptible, high-level
INH-resistant (rpoB, inhAWT and absent katG locus control and katG
WT is lacking)
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Lithuanian isolates
The GTplus assay identified the presence of the katG
S315T1 mutation in all of the INH-resistant Lithuanian
isolates. The data are presented in Table 1. Three of the 26
(12%) isolates with the katG codon 315 gene mutation had
an additional mutation in the inhA promoter region C15T.
Mutation and WT mismatch for katG and inhA correlated in
25 of 26 (96%) isolates. One isolate carried the katG
S315T1 mutation; however, WT was not absent, possibly
indicating a mixture of INH-resistant and -susceptible
bacteria. All of the four different rpoB type mutations
present on the DNA strip were detected in the 21 RIF-
resistant isolates. The most prevalent rpoB mutation was
S531L, accounting for 18 of 21 (86%) isolates. Only one
Lithuanian strain contained both the rpoB S531 and the
rpoB D516Y mutations. One isolate that gave a discrepant
result compared to BACTEC 460TB was fully susceptible
to RIF; however, it showed no rpoB mutations present by
genotype, although the rpoB WT 8 probe was lacking.
Sequencing of this isolate revealed an rpoB L533M
mutation with a nucleotide substitution in codon 533;
CTG (Leu) to ATG (Met), as shown in Table 2.
Danish isolates
The GTplus assay detected a mutation in the inhA promoter
region C15T in 24 of 28 (86%) low-level INH isolates.
Four of the low-level INH-resistant isolates had no
mutations detected by the GTplus assay. Sequencing
revealed that three of the discrepant isolates by BACTEC
460TB had a G→A mutation at position −G49A in the
oxyR–ahpC intergenic region (Table 2). In one of the
isolates, the C-terminal region of the katG 463 region was
Table 1 Comparison of genotypic and phenotypic drug resistance results for Lithuanian isolates
Method Drug concentration (μg/ml) or target genotype probe Interpretable genotypic rpoB, katG or inhA mutation pattern for
number of isolates (n)a
n=15 n=1b n=1 n=1 n=1 n=1 n=1 n=4 n=1c
Phenotypic DSTd RIF (2.0 μg/ml) R R R R R R R S S
INH (0.1 μg/ml) R R R R R R R R R
INH (0.4 μg/ml) R R R R R R R R R
INH (2.0 μg/ml) S R R R R R R S R
rpoB probe WT1e + + + + + + + + +
WT2 + + + + + + + + +
WT3 + + + + - + + + +
WT4 + + + + - + + + +
WT5 + + + + + + + + +
WT6 + + + + + + + + +
WT7 + + + + + - - + +
WT8 - - - - + + + + -
D516V mutation - - - + + - - - -
H526Y mutation - - - - - - + - -
H526D mutation - - - - - + - - -
S531L mutation + + + + - - - - -
katG probe WT - + - - - - - - -
S315T1 mutation + + + + + + + + +
S315T2 mutation - - - - - - - - -
inhA probe WT1 + + - + + - + + -
WT2 + + + + + + + + +
C15T mutation - - + - - + - - +
A16G mutation - - - - - - - - -
T8C mutation - - - - - - - - -
T8A mutation - - - - - - - - -
a R=resistant by BACTEC; S=sensitive by BACTEC; +=band at the respective wild-type (WT) or mutant probe zone; -=absent band at the
respective WT or mutant probe zone
bWT and mutant probe band for katG were present, indicating a mixture of drug-resistant and -susceptible bacteria
cWT 8 and rpoB mutations probe bands were absent
d DST=drug susceptibility testing; RIF=rifampin; INH=isoniazid
eWT=wild-type
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Table 2 Sequencing results of discrepant isolates and samples in comparison to BACTEC
No. of samples/isolates BACTEC resultsa GenoTypeplus Sequencing data
rpoB katG 315 fabG1–inhA oxyR–ahpC katG 463
1 isolate RIF-Sb −rpoB WT8 L533M NDe ND ND ND
2 isolates INH-Rc - ND - - −G49A NAf
1 isolate INH-Rc - ND - - −G49A -
1 isolate INH-Rc - ND - - - NA
4 samples INH-Rd inhA C15T ND - C15T - -
a RIF=rifampin; INH=isoniazid
b RIF-susceptible in BACTEC
c Low-level INH-resistant in BACTEC
dHigh-level INH-resistant in BACTEC
eND=not done
f NA=no amplification or weak amplification
- =no mutation present
−WT=wild-type absent
Table 3 Comparison of genotypic and phenotypic drug resistance results for clinical specimens
Method Drug concentration (μg/ml) or target genotype
probe
Interpretable genotypic rpoB, katG or inhA mutation pattern
for number of specimens (n) a
n=1 n=2b n=5 n=3 n=4c n=7
Phenotypic DSTd RIF (2.0 μg/ml) R R S S S S
INH (0.1 μg/ml) R R R R R R
INH (0.4 μg/ml) R R R R R S
INH (2.0 μg/ml) R R R S S S
rpoB probe WT1e + + + + + +
WT2 + + + + + +
WT3 + + + + + +
WT4 + + + + + +
WT5 + + + + + +
WT6 + + + + + +
WT7 + + + + + +
WT8 - - + + + +
D516V mutation - - - - - -
H526Y mutation - - - - - -
H526D mutation - - - - - -
S531L mutation + + - - - -
katG probe WT - - - - + +
S315T1 mutation + - + + - -
S315T2 mutation - - - - - -
inhA probe WT1 + + + + - -
WT2 + + + + + +
C15T mutation - - - - + +
A16G mutation - - - - - -
T8C mutation - - - - - -
T8A mutation - - - - - -
a R=resistant by BACTEC; S=sensitive by BACTEC; +=band at the respective WT or mutant probe zone; -=absent band at the respective WT or
mutant probe zone
b Samples were culture-negative, NAA-positive, DST was obtained from another culture-positive sample from the same patient (INH high-level
resistant in BACTEC, katG WT was absent and no katG mutations were present)
c Discrepant results (INH high-level resistant in BACTEC and low-level in genotype)
d DST=drug susceptibility testing; RIF=rifampin; INH=isoniazid
eWT=wild-type
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not amplified by PCR and, in two other isolates, only a
weak amplification was observed for this genetic region.
These findings in the katG 463 region were not further
analysed. Three of the five high-level INH-resistant Danish
isolates showed the S315T1 katG mutation. In two of the
five high-level INH-resistant Danish isolates, the genotype
showed that the locus control probe band for the katG gene
was absent, as shown in Fig. 1. These findings indicated
partial deletion of the katG gene, which was verified by
PCR. The genotype correctly identified all 20 Danish INH-
susceptible isolates when compared to BACTEC 460TB.
GTplus performance in clinical specimens
Interpretable GTplus assay results were found in 62 of 81
(77%) clinical specimens tested. The GTplus assay detected
INH resistance correctly in 18 of 22 (82%) INH-resistant
specimens, as shown in Table 3. There were four discrepant
results between the drug susceptibility patterns and those
obtained by the GTplus assay concerning INH resistance.
All had high-level INH resistance with the inhA mutation
C15T, which normally confers low-level INH resistance;
this mutation was confirmed by sequencing (Table 2). Nine
of the 22 (41%) INH-resistant specimens had the katG
S315T1 mutation and 11 of 22 (50%) had the inhA C15T
mutation. The high-level INH-resistant specimens had the
katG S315T1 mutation in 9 of 15 (60%) specimens and the
low-level INH-resistant specimens showed the inhA C15T
mutation in 7 of 7 (100%) specimens. In two INH high-
level resistant specimens, the katG WT was absent;
however, no katG mutations were detected. This was most
probably due to the katG mutation being located elsewhere
in the gene. Only the rpoB S531L mutation was identified
in all RIF-resistant specimens, and all of these were MDR-
TB specimens. Interpretable DNA strip readings were
obtained in 42 of 42 (100%) smear-positive respiratory
specimens and in 6 of 6 (100%) smear-positive non-
respiratory specimens, regardless of the DST result. Only
5 of 19 (26%) respiratory and 9 of 14 (64%) non-
respiratory smear-negative specimens revealed interpretable
genotype results. The data are presented in Table 4.
Discussion
The GTplus assay gave interpretable results when applied
directly in all of the smear-positive clinical specimens,
including both respiratory and non-respiratory samples,
regardless of the drug susceptibility result. However,
interpretable results were only obtained in 42% of the
smear-negative specimens. As the new GTplus version
extensively covers the rpoB mutations responsible for RIF
resistance, the catalase-peroxidase katG codon 315 muta-
tions and, additionally, the enoyl ACP reductase inhA
mutations responsible for INH resistance, the new assay has
the potential for the rapid detection of MDR M. tubercu-
losis in smear-positive specimens.
Previous studies have demonstrated that the first version
of the GT assay, which only included mutations in rpoB and
codon 315 of the katG gene, had a high performance in
Table 4 Performance of the GenoType MDRTBplus (GTplus) assay in primary drug-susceptible and -resistant respiratory and non-respiratory
specimens
Smear resulta M. tuberculosis culture resultb SDAc Number of specimens with interpretable DNA strip reading/number of specimens tested
RIF- and INH-susceptibled RIF- and/or INH-resistantd
Respiratory Non-respiratory Respiratory Non-respiratory
4+ + NDe 8/8 0/0 4/4 0/0
3+ + ND 6/6 0/0 6/6 0/0
2+ + ND 7/7 2/2 4/4 0/0
1+ + ND 3/3 3/3 4/4 1/1
0 + ND 2/6 3/4 1/3 0/0
0 - + 2/2 4/4 0/0 2/2
0 - - 0/8 0/4 0/0 0/0
All positive (%) 24/24 (100) 5/5 (100) 18/18 (100) 1/1 (100)
All negative (%) 4/16 (25) 7/12 (58) 1/3 (33) 2/2 (100)
Total (%) 28/40 (70) 12/17 (70) 19/21 (90) 3/3 (100)
a Smear grade for acid-fast bacilli according to the international standard
b +=positive result; -=negative result
c SDA=strand displacement amplification
d By BACTEC
eND=not done
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isolates. The GT assay detected 92–100% and 67–89% of
the M. tuberculosis strains resistant to RIF and INH,
respectively [5, 20, 21]. Two studies compared the GT
assay with INNO-LiPA Rif.TB (Innogenetics, Zwijnaarde,
Belgium) in 41 and 52 M. tuberculosis isolates, respective-
ly. These studies showed that the genotypic results were
concordant with phenotypic DST for INH in 73% and 90%
of strains, whereas it was 95% and 98% for RIF,
respectively [22, 23]. The advantage of the GT assay
compared to INNO-LiPA Rif.TB is the detection of
resistance to both RIF and INH. Likewise, we found that
RIF resistance was correctly identified by the new assay in
98% of the Lithuanian isolates tested. One strain suscepti-
ble by BACTEC 460TB had an absent rpoB WT band in
the eighth position with no rpoB mutations present on the
DNA strip. Sequencing of this strain revealed an rpoB
L533M mutation, which was not developed in the GTplus
assay. This mutation, which has only rarely been reported,
did not appear to result in a phenotypic change in DST, and
it remains to be determined whether the rpoB L533M
mutation is associated with RIF resistance [24]. The most
prevalent mutation found was the rpoB S531L in 86% of
the Lithuanian isolates. The rpoB S531L mutation was
identified in all Danish RIF-resistant clinical specimens in
concordance with a previous study [25]. Studies have
shown that mutations at codon 531 within the rpoB gene
are the most frequent worldwide [10]. All of the Lithuanian
and Danish high-level INH-resistant isolates were concor-
dant with BACTEC 460TB results. The katG S315T1
mutation accounted for 100% of the INH-resistant Lithua-
nian isolates. Complete deletion of the katG gene is a rare
phenomenon that results in high-level INH resistance [26].
In our study, we found two isolates which showed the
partial absence of the katG gene and high-level INH
resistance in BACTEC 460TB. The low-level INH-resistant
isolates showed a high (86%) correlation between geno-
typic and phenotypic results, indicating that the new
GTplus assay effectively detects low-level INH resistance.
Three isolates had a previously undescribed point mutation
in position −49 (G→A) in the oxy–ahpC region. It is
possible that the identified mutation in position −49 (G49A)
of the oxy–ahpC intergenic region is associated with low-
level INH resistance, but this remains to be further
investigated. Overall, we find that the inclusion of the inhA
probes for INH resistance in the new GTplus version assay
improves the ability of the assay to detect INH resistance.
The first version of the GT assay was optimised for
application directly in pretreated clinical specimens and
was found to have a high performance in several studies. In
106 clinical specimens, interpretable GT results were
achieved in 95% of the 38 smear-positive respiratory
specimens [27]. Another study, which tested the GT assay
directly in 42 smear-positive sputum specimens, found
100% concordance with conventional drug susceptibility
testing [28]. In a study where the GT assay was directly
used in 143 smear-positive specimens, a sensitivity of 94%
for katG and 91% for rpoB was achieved and the assay
correctly identified INH resistance in 84% of specimens
with high-level INH resistance and 96% of specimens with
RIF resistance [29]. Recently, studies on the new extended
GTplus assay have found, similarly to our findings, that it
could be applied directly in smear-positive specimens [30,
31]. One study also included 100 smear-negative M.
tuberculosis specimens and found for RIF interpretable
results in 16 of the 20 (80%) specimens that were culture-
positive [31]. These findings for the smear-negative
samples were higher than our findings.
In conclusion, the GTplus assay is rapid (<48 h) and
easy to perform for the simultaneous detection of RIF and
low- or high-level INH resistance in M. tuberculosis
isolates and clinical specimens obtained from patients
suspected of having TB. Our study demonstrated a high
concordance between GTplus assay resistance patterns and
those obtained by the conventional BACTEC 460TB
system. In laboratories with well-established M. tuberculo-
sis culture and DST systems, we propose that the GTplus
assay should be used as a supplement to the gold standard
DST in obtaining a rapid preliminary DST result, as not all
clinically relevant INH mutations are covered by the assay.
The assay may be applied to smear-positive samples from
patients suspected of treatment failure, recurrent TB, drug-
resistant TB exposure or cases originating from countries
with high levels of drug resistance. However, in countries
that have yet to implement DST, the GTplus assay may be a
valuable tool for the detection of MDR-TB until conven-
tional DST facilities become available. We predict that the
new extended GTplus version assay may be a useful tool
for the World Health Organization (WHO) Global Task
Force to combat and prevent new cases of MDR-TB and
XDR-TB.
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